OKYO vs. IPHA, TELO, CRBU, TIL, TSVT, SGMT, CABA, SAVA, MCRB, and SLDB
Should you be buying OKYO Pharma stock or one of its competitors? The main competitors of OKYO Pharma include Innate Pharma (IPHA), Telomir Pharmaceuticals (TELO), Caribou Biosciences (CRBU), Instil Bio (TIL), 2seventy bio (TSVT), Sagimet Biosciences (SGMT), Cabaletta Bio (CABA), Cassava Sciences (SAVA), Seres Therapeutics (MCRB), and Solid Biosciences (SLDB). These companies are all part of the "pharmaceutical products" industry.
OKYO Pharma vs.
Innate Pharma (NASDAQ:IPHA) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation, community ranking and dividends.
Innate Pharma received 37 more outperform votes than OKYO Pharma when rated by MarketBeat users. However, 100.00% of users gave OKYO Pharma an outperform vote while only 58.44% of users gave Innate Pharma an outperform vote.
Innate Pharma has higher revenue and earnings than OKYO Pharma.
0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Comparatively, 40.5% of OKYO Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Innate Pharma has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.26, suggesting that its share price is 126% less volatile than the S&P 500.
Innate Pharma currently has a consensus price target of $11.50, suggesting a potential upside of 542.46%. OKYO Pharma has a consensus price target of $7.00, suggesting a potential upside of 536.36%. Given Innate Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Innate Pharma is more favorable than OKYO Pharma.
In the previous week, OKYO Pharma had 1 more articles in the media than Innate Pharma. MarketBeat recorded 5 mentions for OKYO Pharma and 4 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 1.19 beat OKYO Pharma's score of 0.76 indicating that Innate Pharma is being referred to more favorably in the media.
Summary
Innate Pharma beats OKYO Pharma on 8 of the 12 factors compared between the two stocks.
Get OKYO Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OKYO Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:OKYO) was last updated on 1/31/2025 by MarketBeat.com Staff
